Patents by Inventor Martin R. Hodge
Martin R. Hodge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110171205Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 25, 2011Publication date: July 14, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
-
Publication number: 20110110915Abstract: A novel human kinase protein and nucleic acid molecule are disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 27, 2010Publication date: May 12, 2011Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventor: Martin R. Hodge
-
Publication number: 20110104706Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 1, 2009Publication date: May 5, 2011Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventor: MARTIN R. HODGE
-
Patent number: 7759085Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 14, 2003Date of Patent: July 20, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Patent number: 7655432Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 7, 2008Date of Patent: February 2, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Publication number: 20090226450Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: April 23, 2009Publication date: September 10, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
-
Publication number: 20090068187Abstract: The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: September 24, 2007Publication date: March 12, 2009Inventors: Maria A. Glucksmann, Rory A.J. Curtis, Fong-Ying Tsai, Martin R. Hodge, Rachel E. Meyers, Kyle J. MacBeth, Rajasekhar Bandaru
-
Publication number: 20080274472Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 7, 2008Publication date: November 6, 2008Inventor: Martin R. Hodge
-
Patent number: 7425424Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 21, 2006Date of Patent: September 16, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Patent number: 7214374Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 9, 2003Date of Patent: May 8, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
-
Patent number: 6858418Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 21, 2001Date of Patent: February 22, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Patent number: 6830914Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 27, 2001Date of Patent: December 14, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, David Yowe
-
Publication number: 20040248160Abstract: The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: February 19, 2004Publication date: December 9, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Maria A. Glucksmann, Rory A.J. Curtis, Fong-Ying Tsai, Martin R. Hodge, Rachel E. Meyers, Kyle J. MacBeth, Rajasekhar Bandaru
-
Publication number: 20040147004Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 9, 2003Publication date: July 29, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
-
Publication number: 20040146939Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 14, 2003Publication date: July 29, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Patent number: 6759221Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 18, 2000Date of Patent: July 6, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Patent number: 6733990Abstract: Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 3, 2000Date of Patent: May 11, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, Clare Lloyd, Nadine S. Weich
-
Publication number: 20040024185Abstract: Isolated nucleic acid molecules encoding a novel protein, NIP45, that interacts with members of the Nuclear Factor of Activated T cell (NF-AT) family of proteins, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed, including methods for detecting NIP45 protein or mRNA in a biological sample, methods of modulating NIP45 activity in a cell, and methods for identifying agents that modulate an interaction between NIP45 and an NF-AT family protein.Type: ApplicationFiled: May 30, 2003Publication date: February 5, 2004Applicant: President and Fellows of Harvard CollegeInventors: Laurie H. Glimcher, Martin R. Hodge
-
Patent number: 6656698Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 1, 2000Date of Patent: December 2, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
-
Publication number: 20030162172Abstract: The present invention relates to a newly identified G-protein-coupled receptor. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using receptor polypeptides and polynucleotides for diagnosis and treatment in receptor-mediated disorders. The invention further relates to methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists useful for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides by recombinant methods.Type: ApplicationFiled: December 18, 2000Publication date: August 28, 2003Inventors: Maria Alexandra Glucksmann, Martin R. Hodge, John J. Hunter, Laura Rudolph-Owen, Nadine S. Weich